Investigating digoxin's effects on infants with heart failure from congenital heart disease
Official title: Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease
Funded at Duke University · NIH-10807963 · Data updated 2026-11-12
This study is looking at how the heart medicine digoxin works in babies with heart failure caused by a specific heart condition, hoping to find better ways to help these little ones feel better and live healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | April 1, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2024 |
| Award (this year) | $629,432 |
| NIH project number | 5R01HD106588-03 |
| Project ID | NIH-10807963 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants diagnosed with single ventricle congenital heart disease who are experiencing heart failure.
✕Less likely to help
Patients with heart failure due to other causes or those who are older than infancy may not benefit from this research.
What this research studies
This research focuses on understanding how the drug digoxin works in infants suffering from heart failure due to single ventricle congenital heart disease. It aims to address the critical lack of effective heart failure treatments for this vulnerable population by studying how digoxin is processed in their bodies and how it affects their heart function. The study will involve careful monitoring of drug levels and heart performance in these infants to identify the best therapeutic approaches. By filling the knowledge gaps in pediatric heart failure treatment, this research hopes to improve survival rates and quality of life for affected infants.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and survival rates for infants with heart failure due to congenital heart disease.
How similar studies have gone: Previous studies have shown promising results with digoxin in similar populations, but this specific approach to understanding its pharmacodynamics in infants is novel.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Hornik, Christoph — Duke University
- Study coordinator: Hornik, Christoph
Related research
Other NIH-funded projects on the same topics.
-
Digoxin effects in infants with single‑ventricle heart failure
This project looks at how the heart drug digoxin behaves and affects newborns and infants who have heart failure from single‑ventricle congenital heart disease.
-
Lipid damage and mitochondria: new ways to protect the Fontan heart
A Stanford-led study aims to find new targets and biomarkers to preserve heart function in children with Fontan circulation by looking at how oxidative stress damages heart cell powerhouses and affects blood vessels.
-
Investigating how mitochondrial injury affects blood vessel function in children with congenital heart disease.
This study is looking at how heart failure affects children who have had a special heart surgery called the Fontan operation, with the goal of finding new ways to spot heart problems early and improve treatments for them.
-
Understanding the genetic and social factors affecting heart failure in people with congenital heart disease
This study is looking at how genes and social factors affect heart failure and survival in people with congenital heart disease, and it's designed to help improve care for those at higher risk.
-
Multimodal AI to improve genetic diagnosis of congenital heart disease
A new AI tool uses multiple types of patient data to help doctors find genetic causes of congenital heart disease more accurately.
-
Multimodal AI to improve genetic diagnosis of congenital heart disease
A big AI project will help doctors and families by better identifying genetic causes of congenital heart defects using imaging, medical data, and genome information.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.